Ajinomoto becomes first partner for Albireo's lead drug elobixibat
This article was originally published in Scrip
Executive Summary
Albireo has struck the first alliance for its lead development project, the bowel disorder drug elobixibat (A3309), with Ajinomoto Pharmaceuticals for a number of Asian markets including Japan.